

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

RESPONSE UNDER 37 CFR, 1.111  
Examining Group 1617  
Patent Application  
Docket No. GJE-6757C1  
Serial No. 10/617,847

September 11, 2007

David Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Layla Soroush  
Art Unit : 1617  
Applicant : Hazel Judith Bardsley *et al.*  
Serial No. : 10/617,847  
Conf. No. : 7988  
Filed : July 10, 2003  
For : New Therapeutic Use of 4-(2-Fluorophenyl)-6- Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA. 22313-1450

RESPONSE UNDER 37 CFR 1.111

Sir:

A Petition and Fee for a two-month Extension of Time is being authorized with the electronic filing of this paper.

In response to the Office Action dated April 11, 2007, the following remarks are respectfully presented.

**Remarks/Arguments** follow the amendment sections of this paper.